A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Our approach is grounded in Prime Editing, a next-generation gene editing technology that enables targeted modifications to genomic DNA without introducing double-stranded breaks. We believe Prime Editing represents the most versatile and precise method for rewriting, replacing, or repairing DNA sequences and may allow us to address a broad spectrum of diseases with an improved safety and specificity profile relative to earlier editing technologies.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | 0 | 0 | 0 |
| Net Income | -201M | -201M | -196M | -198M | -142M | -184M |
| EPS | $-1.35 | $-1.35 | $-1.65 | $-2.18 | $-4.19 | $-14.19 |
| Free Cash Flow | -167M | -167M | -130M | -174M | -148M | -38M |
| ROIC | -284.6% | -136.2% | -104.4% | -121.6% | -44.9% | -28.0% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 1.84 | 0.94 | 0.46 | 0.14 | -0.40 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -208M | -208M | -202M | -205M | -117M | -84M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -166.4% | -146.8% | -127.9% | -148.9% | -177.5% | - |
| Shares Outstanding | 149M | 149M | 119M | 91M | 97M | 97M |
| Metric | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0 | 0 | 0 | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 71M | 87M | 148M | 155M | 161M | 161M |
| SG&A | 14M | 30M | 43M | 50M | 52M | 52M |
| EBIT | -84M | -117M | -205M | -202M | -208M | -208M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -184M | -142M | -198M | -196M | -201M | -201M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | -28.0% | -44.9% | -121.6% | -104.4% | -136.2% | N/M |
| ROE | N/A | -177.5% | -148.9% | -127.9% | -146.8% | -166.4% |
| ROA | -61.0% | -42.9% | -102.2% | -65.8% | -62.8% | -58.7% |
| Cash Flow | ||||||
| Op. Cash Flow | -34M | -132M | -165M | -123M | -163M | -163M |
| Free Cash Flow | -38M | -148M | -174M | -130M | -167M | -167M |
| Owner Earnings | -36M | -141M | -184M | -155M | -199M | -199M |
| CapEx | 4.2M | 16M | 8.7M | 7.3M | 4.5M | 4.5M |
| Maint. CapEx | 568K | 2.2M | 4.7M | 6.1M | 7.3M | 7.3M |
| Growth CapEx | 3.6M | 14M | 4.1M | 1.2M | 0 | 0 |
| D&A | 568K | 2.2M | 4.7M | 6.1M | 7.3M | 7.3M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 1.7M | 6.5M | 14M | 26M | 29M | 29M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | -63M |
| Cash & Equiv. | 185M | 188M | 42M | 182M | 63M | 63M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | -0.40 | 0.14 | 0.46 | 0.94 | 1.84 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | -156M | 316M | 133M | 153M | 121M | 121M |
| Total Assets | 302M | 360M | 194M | 298M | 343M | 343M |
| Total Liabilities | 62M | 44M | 61M | 144M | 222M | 222M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -171M | -293M | -491M | -687M | -888M | -888M |
| Working Capital | 213M | 270M | 87M | 174M | 144M | 144M |
| Current Assets | 271M | 297M | 143M | 212M | 181M | 181M |
| Current Liabilities | 58M | 27M | 56M | 38M | 37M | 37M |
| Per Share Data | ||||||
| EPS | -14.19 | -4.19 | -2.18 | -1.65 | -1.35 | -1.35 |
| Owner EPS | -0.37 | -1.44 | -2.02 | -1.31 | -1.34 | -1.34 |
| Book Value | -1.61 | 3.25 | 1.46 | 1.29 | 0.81 | 0.81 |
| Cash Flow/Share | -0.35 | -1.36 | -1.82 | -1.03 | -1.09 | -1.30 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 97.2M | 97.2M | 90.9M | 118.7M | 149.0M | 149.0M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | -2.7 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 5.7 | 6.5 | 2.2 | 4.3 | 4.6 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | -8.3% | -20.1% | -37.8% | -32.0% | -30.3% |
| Market Cap | N/A | 1.8B | 868M | 344M | 521M | 551M |
| Avg. Price | N/A | 18.02 | 12.81 | 5.45 | 3.17 | 3.70 |
| Year-End Price | N/A | 18.41 | 9.55 | 2.90 | 3.50 | 3.70 |
Prime Medicine, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Prime Medicine, Inc. (PRME) has a 5-year average return on invested capital (ROIC) of -87.0%. This is below average and may indicate limited pricing power.
Prime Medicine, Inc. (PRME) has a market capitalization of $551M. It is classified as a small-cap stock.
Prime Medicine, Inc. (PRME) does not currently pay a regular dividend.
Prime Medicine, Inc. (PRME) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Prime Medicine, Inc. (PRME) generated $-167 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Prime Medicine, Inc. (PRME) has a debt-to-equity ratio of 1.84. This indicates higher leverage, which may increase financial risk.
Prime Medicine, Inc. (PRME) reported earnings per share (EPS) of $-1.35 in its most recent fiscal year.
Prime Medicine, Inc. (PRME) has a return on equity (ROE) of -146.8%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 5 years of financial data for Prime Medicine, Inc. (PRME), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Prime Medicine, Inc. (PRME) has a book value per share of $0.81, based on its most recent annual SEC filing.